Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cytokinetics ( (CYTK) ) just unveiled an update.
Cytokinetics, Incorporated announced that the European Commission has approved MYQORZO (aficamten) tablets in 5 mg, 10 mg, 15 mg and 20 mg doses for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients classified as NYHA class II-III. MYQORZO, an allosteric and reversible inhibitor of cardiac myosin motor activity, now gains regulatory backing in Europe, potentially expanding Cytokinetics’ market presence in cardiovascular therapeutics and providing a new treatment option for patients with this form of heart disease.
The most recent analyst rating on (CYTK) stock is a Hold with a $66.00 price target. To see the full list of analyst forecasts on Cytokinetics stock, see the CYTK Stock Forecast page.
Spark’s Take on CYTK Stock
According to Spark, TipRanks’ AI Analyst, CYTK is a Neutral.
Cytokinetics’ overall score reflects significant financial challenges and valuation concerns, offset by positive corporate events and potential growth from recent FDA approval. The technical analysis suggests neutral momentum, while the earnings call indicates progress but also highlights financial and regulatory risks.
To see Spark’s full report on CYTK stock, click here.
More about Cytokinetics
Cytokinetics, Incorporated is a biopharmaceutical company focused on developing small-molecule therapies targeting cardiac muscle function. Its portfolio includes drugs that modulate cardiac myosin activity, aimed at treating serious cardiovascular diseases such as hypertrophic cardiomyopathy in adult patients.
Average Trading Volume: 1,873,016
Technical Sentiment Signal: Buy
Current Market Cap: $8.1B
See more insights into CYTK stock on TipRanks’ Stock Analysis page.